Navigation Links
Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
Date:5/15/2012

LAUSANNE and VILLARS-SUR-GLÂNE, Switzerland, May 15, 2012 /PRNewswire/ --

Debiopharm Group™ (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement covering the distribution and commercialization in Switzerland of the 1-, 3- and 6-month formulations of Pamorelin® LA and of the 3-month formulation of Salvacyl®. The agreement came into effect on 9 May 2012. Pamorelin® LA, which contains the active substance triptorelin in the form of pamoate salt, is indicated in the treatment of advanced hormone-dependent prostate cancer, endometriosis and female infertility. Salvacyl® is indicated in the treatment of severe sexual deviation in men. The 1- and 3-month formulations of Pamorelin® LA are available immediately, while the introduction of the 6-month formulation of Pamorelin® LA and Salvacyl® will be communicated by Vifor Pharma at a later date.

Developed by Debiopharm, the products Pamorelin® LA and Salvacyl® are manufactured by Debio R.P. in Martigny, Debiopharm's site for applied research, controlled release formulation development and production.

"We are very happy that Vifor Pharma and Debiopharm can offer a drug with the added value of Pamorelin® LA to prostate cancer patients and that Pamorelin® LA will be marketed in Switzerland by a well-established Swiss company such as Vifor Pharma," emphasised Rolland-Yves Mauvernay, founder and President of Debiopharm.

"With Debiopharm we have found a renowned Swiss partner. This move will enable us to provide patients and doctors with an innovative product in the areas of oncology and gynaecology," added Josef Troxler, General Manager of the Swiss affiliate of Vifor Pharma.

About Pamorelin® LA (active ingredient : triptorelin)

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm signed a licensing agreement for triptorelin with Tulane University in the US. Debiopharm developed and registered three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate in Europe and the US. These product formulations are currently available under the names of Trelstar® in the US and Decapeptyl® /Pamorelin® in Europe. In Switzerland, the product received marketing authorization for the treatment of advanced hormone-dependent prostate cancer and endometriosis, as well as for downregulation in association with fertility treatment.

About Debiopharm Group

Debiopharm Group specializes in biopharmaceutical development. The group acquires licences of promising biological products and molecules and develops them further with the objective of achieving global registration. In addition, the group works in the field of diagnostic companions and out-licences to pharmaceutical partners for sales and marketing. The Group finances all its activities independently while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation and regulatory affairs. Established in 1979 and based in Lausanne (Switzerland), Debiopharm Group has developed five products that are commercialized successfully by its partners throughout the world.

Debio R.P., based in Martigny, is a pharmaceutical research, development and production company. The production site of Debio R.P. has been certified by Swissmedic (Switzerland) and ANVISA (Brazil), and inspected and registered by the FDA (USA) and the KFDA (South Korea). Debio R.P. forms part of the Debiopharm Group and employs 130 people, half of whom are university graduates or engineers.

For more information about the Debiopharm Group, please visit: http://www.debiopharm.com.

About Vifor Pharma

Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world. The Swiss affiliate is located in Villars-sur-Glâne (Canton Fribourg).

For more information about Vifor Pharma and its parent company Galenica, please visit http://www.viforpharma.com and http://www.galenica.com.

Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
mwagner@debiopharm.com

Vifor Pharma Media Contact
Beatrix Benz
Head of Global Communications
Vifor Pharma Ltd.
Tel.: +41-58-851-80-00
Fax: +41-58-851-80-03
beatrix.benz@viforpharma.com

Debio R.P. Contact
Cédric Sager
CEO
Tel.: +41(0)27-721-79-00
Fax: +41(0)27-721-79-01
csager@debiopharm.ch    

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk
   


In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com
   



'/>"/>
SOURCE The Debiopharm Group and Vifor Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
2. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
3. Continuity as Debiopharm Group™ Management Moves Forward
4. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
5. Debiopharm Group™ and Aurigene Nominate Development Candidate
6. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
7. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
8. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
11. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):